Thursday, March 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Chemical Defense Pharmaceuticals for Nerve Agent Soman

by Global Biodefense Staff
March 4, 2014
Nerve and Blister Agent Protective Gear
Nerve and Blister Agent Protective Gear. Credit: USA.gov

The U.S. Department of Defense recently issued a Request for Information (RFI) to conduct market research for manufacturing capabilities for a nerve agent pretreatment for use by military personnel.

The military currently procures a pretreatment for use prior to exposure to the chemical nerve agent soman, as part of Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP). Each tablet contains 30 mg of pyridostigmine bromide, as an orally active cholinesterase inhibitor, and is supplied in sealed blister or strip packaging within a protective sleeve.

The annual estimated quantity under the current contract is 36,000 blister packages containing 21 tablets each (or 756,000 tablets) per year. The current manufacturer of this product is Valeant Pharmaceuticals International.

System requirements include manufacturing capability to produce pyridostigmine bromide in the doses currently procured by the DoD, to include labeling, packaging and shipping configurations. The storage conditions and shelf life should be identical to. SNAPP.

The U.S. Army Office of The Surgeon General (OTSG) sponsors the SNAPP New Drug Application (NDA), approved in February 2003. It is anticipated that interested parties would become either a contract manufacturer under the OTSG NDA, or could potentially submit their own Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). 

This effort is managed by the Medical Countermeasure Systems – Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office which is responsible for the development, procurement, fielding, and sustaining of medical treatment and prophylactic capabilities against chemical, radiological and nuclear threats.

Further details are available under Solicitation Number: W911QY14SCDP3. 

Tags: JPEO-CBRNDRFI

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy